Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.
作者信息
Kripp Melanie, Hofheinz Ralf-Dieter
机构信息
Onkologisches Zentrum, III Medizinische Klinik, Medizinische Fakultät Mannheim der Universität, Heidelberg, Germany.
出版信息
Int J Nanomedicine. 2008;3(4):397-401. doi: 10.2147/ijn.s3259.
Abstract
Liposomal encapsulated cytarabine (DepoCyte, Mundipharma GmbH, Limburg/Lahn, Germany) is a slow-release formulation of conventional cytarabine. It is licensed for intrathecal use in patients with lymphomatous and leukemic meningitis. DepoCyte obtained superior response rates, improved patient quality of life and improved the time to neurological progression in a randomized albeit small clinical trial. In this review we briefly summarize the clinical data and discuss them in light of clinical problems and possible treatment scenarios.
摘要
相似文献
1
Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.
Int J Nanomedicine. 2008;3(4):397-401. doi: 10.2147/ijn.s3259.
2
Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments.
Expert Opin Pharmacother. 2008 Feb;9(2):301-9. doi: 10.1517/14656566.9.2.301.
3
Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.
Clin Transl Oncol. 2005 Jul;7(6):232-8. doi: 10.1007/BF02710168.
4
Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Invest New Drugs. 2012 Aug;30(4):1697-702. doi: 10.1007/s10637-011-9632-6. Epub 2011 Jan 13.
5
Clinical experience using intrathecal liposomal cytarabine to manage neoplastic meningitis in three patients with acute promyelocytic leukemia.
Leuk Res. 2011 Jul;35(7):e128-30. doi: 10.1016/j.leukres.2011.03.023. Epub 2011 Apr 17.
6
Liposomal cytarabine: new drug. Lymphomatous meningitis: no better than standard cytarabine.
Prescrire Int. 2006 Feb;15(81):11-2.
7
New liposomal cytarabine formulation in CSF.
Clin Lab. 2010;56(1-2):69-70.
8
Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
Ann Hematol. 2008 Dec;87(12):1009-12. doi: 10.1007/s00277-008-0546-0. Epub 2008 Aug 13.
9
Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
Int J Hematol. 2007 Jul;86(1):33-6. doi: 10.1532/IJH97.E0704.
10
A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study.
J Neurooncol. 2007 Jan;81(2):201-8. doi: 10.1007/s11060-006-9218-x. Epub 2006 Aug 29.
引用本文的文献
1
Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.
Curr Pharm Des. 2025;31(23):1844-1865. doi: 10.2174/0113816128338217250114073640.
2
Nanomedicinal products: a survey on specific toxicity and side effects.
Int J Nanomedicine. 2017 Aug 22;12:6107-6129. doi: 10.2147/IJN.S139687. eCollection 2017.
3
Marketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for success.
Mar Drugs. 2014 Feb 17;12(2):1066-101. doi: 10.3390/md12021066.
4
Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome.
Clin Investig (Lond). 2011 Oct;1(10):1391-1402. doi: 10.4155/cli.11.115.
5
Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Invest New Drugs. 2012 Aug;30(4):1697-702. doi: 10.1007/s10637-011-9632-6. Epub 2011 Jan 13.
6
Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma.
J Neurooncol. 2011 Jul;103(3):635-40. doi: 10.1007/s11060-010-0435-y. Epub 2010 Oct 17.
本文引用的文献
1
Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
Leuk Lymphoma. 2014 Aug;55(8):1739-42. doi: 10.3109/10428194.2013.853765. Epub 2013 Nov 25.
2
Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments.
Expert Opin Pharmacother. 2008 Feb;9(2):301-9. doi: 10.1517/14656566.9.2.301.
3
Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma.
Leuk Lymphoma. 2007 Sep;48(9):1849-51. doi: 10.1080/10428190701573232.
4
Toward optimal use of intrathecal liposomal cytarabine.
Leuk Lymphoma. 2007 Sep;48(9):1672-3. doi: 10.1080/10428190701573687.
5
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Eur J Clin Invest. 2007 Oct;37(10):808-13. doi: 10.1111/j.1365-2362.2007.01859.x. Epub 2007 Aug 28.
6
Re: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
Blood. 2007 Sep 1;110(5):1698; author reply 1698-9. doi: 10.1182/blood-2007-02-073536.
7
Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.
Int J Hematol. 2007 Jul;86(1):33-6. doi: 10.1532/IJH97.E0704.
8
CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies.
Neurology. 2007 May 15;68(20):1674-9. doi: 10.1212/01.wnl.0000261909.28915.83.
9
Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
J Pediatr Hematol Oncol. 2007 Apr;29(4):222-6. doi: 10.1097/MPH.0b013e318041f112.
10
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
Blood. 2007 Apr 15;109(8):3214-8. doi: 10.1182/blood-2006-08-043646. Epub 2007 Jan 5.
Zotero 插件